1. Hepatocellular type II fibrinogen inclusions in a patient with severe COVID-19 and hepatitis
- Author
-
Lorenzo Alberio, Marguerite Neerman-Arbez, Montserrat Fraga, Darius Moradpour, Alessandro Casini, Antoine G. Schneider, Haithem Chtioui, Christine Sempoux, Elodie Romailler, Florent Artru, and Jonathan Tschopp
- Subjects
0301 basic medicine ,Risk ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Low-Molecular-Weight/therapeutic use ,ground-glass hepatocyte ,Fibrinogen ,Article ,Venous Thromboembolism/epidemiology/prevention & control ,Betacoronavirus/isolation & purification ,COVID-19 ,Coronavirus Infections/diagnosis ,Coronavirus Infections/physiopathology ,Diagnosis, Differential ,Fibrinogen/analysis ,Glycogen Storage Disease Type IV/diagnosis ,Hepatitis/etiology ,Hepatitis/pathology ,Hepatitis/physiopathology ,Hepatitis B, Chronic/diagnosis ,Humans ,Inclusion Bodies/pathology ,Lafora Disease/diagnosis ,Liver/diagnostic imaging ,Liver/pathology ,Liver Function Tests/methods ,Male ,Middle Aged ,Pandemics ,Patient Care Management/methods ,Pneumonia, Ventilator-Associated/therapy ,Pneumonia, Viral/diagnosis ,Pneumonia, Viral/physiopathology ,Pulmonary Embolism/diagnosis ,Pulmonary Embolism/etiology ,Pulmonary Embolism/physiopathology ,Respiration, Artificial/adverse effects ,Respiration, Artificial/methods ,SARS-CoV-2 ,Treatment Outcome ,Pulmonary Embolism/epidemiology/prevention & control ,03 medical and health sciences ,Betacoronavirus ,0302 clinical medicine ,Internal medicine ,fibrinogen storage disease ,Medicine ,hepatitis ,ddc:576.5 ,cardiovascular diseases ,Heparin/therapeutic use ,Hepatitis ,ddc:616 ,Hepatology ,business.industry ,Critically ill ,Heparin ,Guidance documents ,Pneumonia ,medicine.disease ,equipment and supplies ,Viral/epidemiology ,030104 developmental biology ,Anticoagulants/therapeutic use ,Fondaparinux/therapeutic use ,Practice Guidelines as Topic ,Venous Thrombosis/epidemiology/prevention & control ,030211 gastroenterology & hepatology ,Coronavirus Infections/epidemiology ,Differential diagnosis ,business ,Venous thromboembolism ,medicine.drug - Abstract
Many centres have noticed a high number of venous thromboembolism (VTE) events among critically ill inpatients with COVID-19 pneumonia. The aims of this study were (1) to summarise the reported risk of VTE associated with COVID-19 infections and (2) to summarise guidance documents on thromboprophylaxis in COVID-19 patients, in a systematic review.
- Published
- 2020